PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16428938-0	2006	Recombinant interleukin-2 pre-treatment increases anti-tumor response to paclitaxel by affecting lung P-glycoprotein expression on the Lewis lung carcinoma.	Paclitaxel	73-83	interleukin 2	Mus musculus	12-25	
18508881-0	2008	Effect of interleukin-2 pretreatment on paclitaxel absorption and tissue disposition after oral and intravenous administration in mice.	Paclitaxel	40-50	interleukin 2	Mus musculus	10-23	
11914641-0	2002	Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice.	Paclitaxel	74-84	interleukin 2	Mus musculus	12-25	
15663292-0	2004	Enhanced oral bioavailability of paclitaxel by recombinant interleukin-2 in mice with murine Lewis lung carcinoma.	Paclitaxel	33-43	interleukin 2	Mus musculus	59-72	
15663292-1	2004	The effect of recombinant interleukin-2 (rIL-2) pretreatment on the pharmacokinetics of paclitaxel was investigated in the murine Lewis lung carcinoma model in C57B1/6 mice.	Paclitaxel	88-98	interleukin 2	Mus musculus	26-39	
15378273-0	2005	Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2.	Paclitaxel	44-54	interleukin 2	Mus musculus	100-113	
15378273-3	2005	In the work described here, the effects of interleukin-2 pretreatment on pharmacokinetics and toxicity of paclitaxel orally administered were investigated.	Paclitaxel	106-116	interleukin 2	Mus musculus	43-56	
35281908-12	2022	JG remarkably enhanced the anticancer effect of PTX by increasing the red blood cell and platelet counts; increasing hemoglobin, interleukin (IL)-2, and tumor necrosis factor-alpha levels; increasing CD4+T cells and the CD4+/CD8+ ratio; and decreasing IL-10 levels.	Paclitaxel	48-51	interleukin 2	Mus musculus	129-147	
1350792-5	1992	But Taxol seemed to be a weak inducer of the two interleukins IL-1 and IL-2, since their detection occurred late in the cell culture supernatants.	Paclitaxel	4-9	interleukin 2	Mus musculus	71-75	
32401077-8	2020	In addition, PTX + SPS-NEs significantly inhibited tumor growth by 72.82% and increased the secretion of serum IL-2, TNF-alpha and IFN-gamma.	Paclitaxel	13-16	interleukin 2	Mus musculus	111-115	
35214172-10	2022	IMT/PTX resulted in significantly more necrotic tumor tissue and increased levels of IL-2, 4, and 12 compared to control.	Paclitaxel	4-7	interleukin 2	Mus musculus	85-89	
32943934-8	2020	Moxibustion combined with paclitaxel increased the number of white blood cells, thymus index, and spleen index, and enhanced immune function by upregulating interferon-gamma and interleukin-2 and downregulating interleukin-10 and transforming growth factor-beta1.	Paclitaxel	26-36	interleukin 2	Mus musculus	178-191	
2900642-6	1988	The responding ability of taxol-treated lymphocytes is not restored to control levels by the addition of interleukin 2, leading to the suggestion that interleukin 2 receptors do not emerge or function normally in these cells.	Paclitaxel	26-31	interleukin 2	Mus musculus	151-164